Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISA...

Descripción completa

Detalles Bibliográficos
Autores principales: Jääskeläinen, Anne J, Kekäläinen, Eliisa, Kallio-Kokko, Hannimari, Mannonen, Laura, Kortela, Elisa, Vapalahti, Olli, Kurkela, Satu, Lappalainen, Maija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2020
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219034/
https://www.ncbi.nlm.nih.gov/pubmed/32400364
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.18.2000603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219034/
https://www.ncbi.nlm.nih.gov/pubmed/32400364
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.18.2000603

Ejemplares similares